Background The hollow-fibre system model of tuberculosis (HFS-TB) has been endorsed by
regulators; however, application of HFS-TB requires a thorough understanding of intra-and …

Objectives The standard of care (SOC) for the treatment of pulmonary Mycobacterium avium
complex (MAC) disease (clarithromycin, rifabutin, and ethambutol) achieves sustained …

Aim: We report the prevalence and effect of genetic variability on pharmacokinetic
parameters of isoniazid and rifampicin. Materials & methods: Genotypes for SLCO1B1 …

Objectives To study 2 h plasma concentrations of the first-line tuberculosis drugs isoniazid,
rifampicin, ethambutol and pyrazinamide in a cohort of patients with tuberculosis in Denmark …

Introduction: WHO global strategy is to end tuberculosis epidemic by 2035. Pharmacokinetic
and pharmacogenetic studies are increasingly performed and might confirm their potential …

Objectives There is a paucity of evidence regarding the optimal dosing of anti-TB drugs in
children. The aim of this study was to identify the pharmacokinetic parameters of first-line …

Levofloxacin is increasingly used in the treatment of multidrug-resistant tuberculosis (MDR-
TB). There are limited pediatric pharmacokinetic data to inform dose selection for children …

Background. The in vitro hollow fiber system model of tuberculosis (HFS-TB), in tandem with
Monte Carlo experiments, was introduced more than a decade ago. Since then, it has been …

Pyrazinamide is a potent sterilising agent that shortens the treatment duration needed to
cure tuberculosis. It is synergistic with novel and existing drugs for tuberculosis. The dose of …

Rationale: Standardized dosing of antitubercular drugs contributes to a substantial
incidence of toxicities, inadequate treatment response, and relapse, in part due to variable …